Physician profile
Daniel Gorman Kramer
NPI 1831305150
$3,389.55
in general payments reported to CMS, 2019-2025
21 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,105 · 2020: $336 · 2021: $170 · 2022: $281 · 2023: $216 · 2024: $1,169 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $938 · Food and Beverage: $559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $938.07 |
| Food and Beverage | $559.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,069.13 | 2024 | Evera Mri Xt Dr Surescan |
| Janssen Pharmaceuticals, INC | $432.50 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $359.37 | 2019-2025 | Wainua, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $266.04 | 2019-2022 | |
| Baxter Healthcare | $238.76 | 2022-2023 | Hillrom - Carnation Ambulatory Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.77 | 2019-2022 | |
| Amgen INC. | $147.12 | 2019-2022 | |
| Amarin Pharma, INC. | $109.48 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $106.11 | 2019-2025 | |
| Pfizer INC. | $89.21 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $81.22 | 2019 | |
| Sanofi-Aventis U.S. LLC | $65.93 | 2019 | |
| Welch Allyn | $56.85 | 2021 | |
| Bardy Diagnostics, INC. | $34.97 | 2019-2020 | |
| Preventice Services, LLC | $33.99 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $28.74 | 2021 | |
| Medicomp INC | $26.46 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $26.25 | 2019 | |
| Lilly USA, LLC | $25.21 | 2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $24.57 | 2025 | Wegovy |
| Arbor Pharmaceuticals, INC. | $16.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.